Alaye siwaju sii ― Yoruba

Lesa Q-switched Nd:YAG ni a mọ lati ṣe itọju nevus ti Ota daradara ati awọn ipo ti o jọra. A ṣe iwadii kan lati rii bi ina lesa high-fluence 1064 nm Q-switched Nd:YAG ṣe ṣiṣẹ daradara lori awọn aaye Mongolian ni awọn agbegbe dani, laisi fa awọ ara lati tan. A ṣe iwadi awọn alaisan 61 pẹlu awọn aaye wọnyi, ṣe ayẹwo lapapọ awọn ọgbẹ 70. Idaji awọn ọgbẹ ni a ṣe itọju pẹlu laser, nigba ti awọn miiran ko ni itọju fun lafiwe. A ṣe ayẹwo awọn abajade nipa lilo iwọn ati ẹrọ kan ti a npe ni Mexameter® lati wiwọn awọn ipele melanin. Awọn alaisan ni a tẹle fun apapọ awọn osu 14 ni ẹgbẹ itọju ati awọn osu 18 ni ẹgbẹ akiyesi. Ni ipari iwadi naa, a ri awọn iyatọ ti o pọju ninu awọn iṣiro iwọn ati awọn ipele melanin laarin awọn ẹgbẹ ti a ṣe itọju ati ti ko ni itọju, pẹlu ẹgbẹ ti a ṣe itọju laser ti o nfihan awọn esi to dara julọ. Lesa high-fluence Q-switched Nd:YAG , laisi nfa imole awọ ara, fihan pe o munadoko ati ailewu fun atọju awọn aaye Mongolian dani wọnyi.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.

A ṣe iwadi imunadoko ati ailewu ti lilo itọju laser kan pato fun ABNOM , ati wo kini awọn nkan ti o le ni ipa bi o ṣe n ṣiṣẹ daradara. A wo awọn alaisan 110 ti wọn ni ABNOM ati pe o wa laarin awọn itọju laser meji si mẹsan. A rii pe itọju naa ṣiṣẹ daradara bi o ti pẹ to, ṣugbọn kii ṣe daradara ni awọn alaisan agbalagba. O tun ṣiṣẹ daradara ni awọn alaisan ti o ni awọ fẹẹrẹfẹ (iru III) ati awọn agbegbe ti o kan kere (kere ju 10 cm2) . Nini melasma pẹlu ABNOM jẹ ki itọju naa ko munadoko. Awọ tabi nọmba awọn agbegbe ti o kan ko dabi lati ṣe iyatọ. O fẹrẹ to 10% ti awọn alaisan ni awọn aaye dudu lẹhin itọju. Itọju pupọ ni kutukutu fun awọn abajade to dara. Awọn alaisan agbalagba ti o ni awọ dudu ati awọn aaye dudu ni o le ni awọn aaye dudu lẹhin itọju. Fun awọn alaisan ti o ni ABNOM ati melasma, o dara lati lo lesa agbara kekere lati yago fun ṣiṣe melasma naa buru si.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.